X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (17963) 17963
Book Review (1580) 1580
Publication (1531) 1531
Newsletter (194) 194
Book Chapter (37) 37
Conference Proceeding (33) 33
Newspaper Article (32) 32
Magazine Article (19) 19
Dissertation (12) 12
Book / eBook (11) 11
Government Document (8) 8
Paper (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (16436) 16436
humans (9914) 9914
male (9434) 9434
animals (9393) 9393
pyridines - pharmacology (7608) 7608
female (5571) 5571
pyridines - administration & dosage (5016) 5016
rats (4862) 4862
pyridines - therapeutic use (4246) 4246
pharmacology & pharmacy (3688) 3688
middle aged (3201) 3201
mice (3058) 3058
adult (2935) 2935
dose-response relationship, drug (2500) 2500
aged (2353) 2353
pyridines - adverse effects (2299) 2299
oncology (1984) 1984
neurosciences (1925) 1925
rats, sprague-dawley (1739) 1739
administration, oral (1722) 1722
pyridines - pharmacokinetics (1648) 1648
treatment outcome (1465) 1465
time factors (1375) 1375
cancer (1313) 1313
analysis (1312) 1312
imidazoles - pharmacology (1280) 1280
pyridine (1275) 1275
abridged index medicus (1200) 1200
disease models, animal (1159) 1159
rats, wistar (1124) 1124
research (1036) 1036
pyridines - chemistry (1024) 1024
drug administration schedule (984) 984
niacinamide - analogs & derivatives (973) 973
biochemistry & molecular biology (936) 936
care and treatment (914) 914
phenylurea compounds (907) 907
drug therapy (886) 886
expression (869) 869
article (850) 850
pyridines (848) 848
piperazines - pharmacology (839) 839
cell line, tumor (798) 798
enzyme inhibitors - pharmacology (796) 796
chemistry, medicinal (789) 789
antineoplastic agents - therapeutic use (775) 775
double-blind method (759) 759
drug interactions (759) 759
antineoplastic combined chemotherapy protocols - therapeutic use (729) 729
pharmacokinetics (727) 727
pyridines - metabolism (718) 718
drug combinations (711) 711
mice, inbred c57bl (705) 705
blood pressure - drug effects (693) 693
drug therapy, combination (682) 682
medicine & public health (661) 661
activation (656) 656
psychiatry (650) 650
structure-activity relationship (647) 647
apoptosis (645) 645
brain (643) 643
cells, cultured (627) 627
in vitro techniques (622) 622
rodents (621) 621
cell biology (618) 618
health aspects (616) 616
pharmacology (611) 611
chemotherapy (607) 607
dogs (607) 607
toxicology (604) 604
aged, 80 and over (602) 602
rat (602) 602
in-vivo (599) 599
pharmacology/toxicology (596) 596
cardiac & cardiovascular systems (595) 595
pyridines - blood (593) 593
in-vitro (592) 592
therapy (592) 592
inhibition (572) 572
signal transduction - drug effects (570) 570
clinical trials as topic (561) 561
cells (559) 559
adolescent (558) 558
protein kinase inhibitors - therapeutic use (557) 557
brain - metabolism (545) 545
physiological aspects (542) 542
antineoplastic agents - pharmacology (539) 539
protein kinase inhibitors - pharmacology (531) 531
pyridines - toxicity (526) 526
serotonin antagonists - pharmacology (524) 524
phosphorylation (519) 519
sorafenib (519) 519
hiv infections - drug therapy (518) 518
proteins (517) 517
young adult (509) 509
dosage and administration (500) 500
peripheral vascular disease (498) 498
atazanavir sulfate (497) 497
drugs (496) 496
cell proliferation - drug effects (489) 489
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (17166) 17166
Japanese (414) 414
German (205) 205
Russian (115) 115
French (108) 108
Italian (70) 70
Spanish (61) 61
Chinese (43) 43
Polish (19) 19
Czech (12) 12
Hungarian (8) 8
Swedish (6) 6
Danish (4) 4
Norwegian (4) 4
Ukrainian (4) 4
Dutch (3) 3
Korean (2) 2
Portuguese (2) 2
Bulgarian (1) 1
Hebrew (1) 1
Romanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2429 - 2438
Summary Background The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI),... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | TREATMENT-NAIVE | PHARMACOKINETICS | RALTEGRAVIR | SAFETY | EFAVIRENZ | ADULTS | SINGLE-TABLET REGIMEN | PATIENTS 96-WEEK EFFICACY | COMBINATION | ADHERENCE | HIV-1 | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Atazanavir Sulfate | Adult | Female | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Ritonavir - administration & dosage | Deoxycytidine - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Quinolones - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Antiretroviral drugs | Bone density | Pharmaceutical industry | Human immunodeficiency virus--HIV | Pneumonia | Laboratories | Ritonavir | Liver | Infections | Drug resistance | Hepatitis | Randomization | All terrain vehicles | Creatinine | Integrase | Data processing | Proteinase inhibitors | Behavior disorders | Ribonucleic acid--RNA | Patients | Cholesterol | Glomerular filtration rate | Inhibitors | Protease inhibitors | Interactive systems | Index Medicus | Abridged Index Medicus
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | Index Medicus | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes | Index Medicus | Abridged Index Medicus
Journal Article
AIDS, ISSN 0269-9370, 09/2007, Volume 21, Issue 14, pp. 1899 - 1907
Objectives: To describe first dose and steady state antiretroviral drug exposure in the female genital tract. Design: Non-blinded, single center, open-label... 
Women | Genital tract | HIV | Prophylaxis | Sexual transmission | Pharmacokinetics | Antiretroviral therapy | genital tract | INFECTIOUS DISEASES | sexual transmission | antiretroviral therapy | EMTRICITABINE | IMMUNOLOGY | CEREBROSPINAL-FLUID | prophylaxis | BACTERIAL VAGINOSIS | PROTEASE INHIBITOR | TRICHOMONAS-VAGINALIS | HIV-INFECTION | THERAPY | VIROLOGY | LIQUID-CHROMATOGRAPHY | SIMIAN IMMUNODEFICIENCY VIRUS | pharmacokinetics | MACAQUES | women | Lamivudine - administration & dosage | Humans | Deoxycytidine - blood | Zidovudine - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Genitalia, Female - metabolism | Emtricitabine | HIV Infections - blood | HIV Protease Inhibitors - blood | Adenine - analogs & derivatives | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Administration, Oral | Anti-Retroviral Agents - pharmacokinetics | Deoxycytidine - administration & dosage | Lopinavir | HIV Protease Inhibitors - administration & dosage | Adenine - pharmacokinetics | Pyrimidinones - blood | Anti-Retroviral Agents - administration & dosage | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Zidovudine - blood | Deoxycytidine - analogs & derivatives | Reverse Transcriptase Inhibitors - blood | Zidovudine - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Adult | Benzoxazines - blood | Female | Organophosphonates - blood | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Lamivudine - blood | Lamivudine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | HIV Infections - drug therapy | Index Medicus | AIDS/HIV
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 01/2009, Volume 101, Issue 1, pp. 77 - 85
Dabigatran etexilate has been investigated in three phase III trials for the prevention of venous thromboembolism (VTE). Health technology assessment agencies... 
anticoagulants | thrombosis | prophylaxis | Embolism | Meta-analysis | Anticoagulants | Thrombosis | Prophylaxis | ENOXAPARIN | meta-analysis | RANDOMIZED-TRIAL | REPLACEMENT | ORTHOPEDIC-SURGERY | MOLECULAR-WEIGHT HEPARIN | THROMBOSIS PROPHYLAXIS | US HOSPITALS | PERIPHERAL VASCULAR DISEASE | THROMBOPROPHYLAXIS | HEMATOLOGY | UNFRACTIONATED HEPARIN | REGISTRY | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Arthroplasty, Replacement, Knee - adverse effects | Humans | Dabigatran | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Clinical Trials, Phase III as Topic | Enoxaparin - administration & dosage | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Drug Administration Schedule | Risk Assessment | Administration, Oral | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Arthroplasty, Replacement, Hip - adverse effects | Venous Thromboembolism - etiology | Hemorrhage - chemically induced | Index Medicus | Administration | Phase III as Topic | Benzimidazoles/administration & dosage/adverse effects/therapeutic use | Pyridines/administration & dosage/adverse effects/therapeutic use | Arthroplasty | Replacement | Oral | Clinical Trials | Kirurgi | Knee/adverse effects | Hemorrhage/chemically induced | Venous Thromboembolism/etiology/mortality/prevention & control | Hip/adverse effects | Anticoagulants/administration & dosage/adverse effects/therapeutic use | Surgery | Enoxaparin/administration & dosage/adverse effects/therapeutic use
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 2014, Volume 111, Issue 5, pp. 981 - 988
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 25 - 35
Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EXEMESTANE | ONCOLOGY | CELL-CYCLE | POSTMENOPAUSAL WOMEN | HER2 | PLUS | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Triazoles - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Molecular Targeted Therapy | North America | Nitriles - administration & dosage | Breast Neoplasms - enzymology | Time Factors | Postmenopause | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Republic of Korea | Aromatase Inhibitors - administration & dosage | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Europe | Proportional Hazards Models | Cyclin-Dependent Kinase Inhibitor p16 - genetics | Treatment Outcome | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Cyclin D1 - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | South Africa | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Care and treatment | Oncology, Experimental | Estrogen | Breast cancer | Research | Antineoplastic agents | Phosphotransferases | Cancer | Index Medicus
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 07/2009, Volume 157, Issue 5, pp. 831 - 843
Background and purpose:  Buprenorphine displays attributes of opioids, but also some features distinct from them. We examined spinal and supraspinal signal... 
mechanism of action | supraspinal | buprenorphine | analgesia (antinociception) | Supraspinal | Analgesia (antinociception) | Buprenorphine | Mechanism of action | MOLECULAR REARRANGEMENTS | OKADAIC-ACID | ANTISENSE OLIGODEOXYNUCLEOTIDES | MU-OPIOID RECEPTOR | INTRINSIC EFFICACY | SERINE/THREONINE PROTEIN PHOSPHATASES | PARTIAL AGONIST | PHARMACOLOGY & PHARMACY | MORPHINE-THEBAINE GROUP | TAIL-FLICK TEST | INDUCED ANTINOCICEPTION | Fentanyl - administration & dosage | Piperazines - administration & dosage | Narcotic Antagonists - administration & dosage | Serotonin Antagonists - administration & dosage | Phosphoprotein Phosphatases - metabolism | Aminoquinolines - administration & dosage | Injections, Intraventricular | Oligonucleotides, Antisense - metabolism | Male | Opioid Peptides - administration & dosage | Pain - chemically induced | Adrenergic alpha-Antagonists - administration & dosage | Pain - metabolism | GTP-Binding Proteins - genetics | Okadaic Acid - administration & dosage | Brain - metabolism | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Benzamides - administration & dosage | Pain Threshold - drug effects | Anesthetics, Local - administration & dosage | Pertussis Toxin - administration & dosage | Receptor, Serotonin, 5-HT1A - metabolism | Disease Models, Animal | Receptors, Opioid - metabolism | Injections, Spinal | Pyridines - administration & dosage | Pain - prevention & control | Phosphoprotein Phosphatases - antagonists & inhibitors | Yohimbine - administration & dosage | Brain - drug effects | Buprenorphine - administration & dosage | Animals | Signal Transduction - drug effects | Analgesics, Opioid - administration & dosage | Acetylcholine | Mice | Naloxone - administration & dosage | Pain Measurement | Morphine - administration & dosage | Receptors, Opioid - drug effects | Serotonin 5-HT1 Receptor Antagonists | GTP-Binding Proteins - metabolism | Index Medicus | Research Papers
Journal Article